These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6974026)

  • 1. [Immunogenetic variants of mouse tumor cells obtained by mutagenesis].
    Boon T
    Bull Mem Acad R Med Belg; 1980; 135(10):674-83. PubMed ID: 6974026
    [No Abstract]   [Full Text] [Related]  

  • 2. Tum- variants and the detection of tumor-specific transplantation antigens on spontaneous mouse tumors.
    Boon T; van Pel A; Uyttenhove C; Marchand M; Lambotte P
    Behring Inst Mitt; 1984 May; (74):209-13. PubMed ID: 6332616
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutagen-induced antigenic variants of tumor cells.
    Boon T; Van Pel A; De Plaen E; Vessière F
    Symp Fundam Cancer Res; 1986; 38():139-48. PubMed ID: 3489258
    [No Abstract]   [Full Text] [Related]  

  • 4. Antigenic tumor cell variants obtained with mutagens.
    Boon T
    Adv Cancer Res; 1983; 39():121-51. PubMed ID: 6353885
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunogenic variants induced by mutagens: a mechanism for generating autoimmune responses to tumors.
    Frost P
    Immunol Ser; 1990; 52():53-64. PubMed ID: 2091787
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer. Awakening immunity.
    Schreiber H; Rowley DA
    Science; 2010 Nov; 330(6005):761-2. PubMed ID: 21051618
    [No Abstract]   [Full Text] [Related]  

  • 7. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
    Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
    Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Host's immune responses against tumor].
    Fujiwara H
    Rinsho Byori; 1989 Jul; (Spec No 82):35-41. PubMed ID: 2614962
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. I. Effect of incompatibilities at H-2 or non-H-2 genes in normal and nude (nu/nu) mice.
    Schirrmacher V
    Invasion Metastasis; 1981; 1(1):4-21. PubMed ID: 7188381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the role of unmutated antigens in tumor rejection in mice with unperturbed T-cell repertoires.
    Sarma S; Bai XF; Liu JQ; May KF; Zheng P; Liu Y
    Cancer Res; 2003 Sep; 63(18):6051-5. PubMed ID: 14522934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Foreign H-2-like alloantigens of syngeneic tumor cells can act as new "restriction" molecules for the associative recognition of non-H-2 or tumor-associated antigens by lymphoid effectors in the cytostasis assay.
    Festenstein H; de Giorgi L; Matossian-Rogers A
    Transplant Proc; 1981 Dec; 13(4):1877-9. PubMed ID: 7330973
    [No Abstract]   [Full Text] [Related]  

  • 13. Demonstration of a correlation between tumor cell H-2 antigen content, immunogenicity, and tumorigenicity using lectin-resistant tumor variants.
    Dennis JW; Donaghue TP; Carlow DA; Kerbel RS
    Cancer Res; 1981 Oct; 41(10):4010-9. PubMed ID: 6974593
    [No Abstract]   [Full Text] [Related]  

  • 14. Genomic aspects of drug-induced xenogenization of murine tumors.
    Fuschiotti P; Grohmann U; Allegrucci M; Nardelli B; Fioretti MC
    Pharmacol Res; 1992; 25 Suppl 1():19-20. PubMed ID: 1354858
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.
    Cui Y; Kelleher E; Straley E; Fuchs E; Gorski K; Levitsky H; Borrello I; Civin CI; Schoenberger SP; Cheng L; Pardoll DM; Whartenby KA
    Nat Med; 2003 Jul; 9(7):952-8. PubMed ID: 12778137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.
    Stewart TJ; Smyth MJ; Fernando GJ; Frazer IH; Leggatt GR
    Cancer Res; 2003 Jun; 63(12):3058-60. PubMed ID: 12810627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Activated T-lymphocytes--a mode of physiological tumor defence].
    Röllinghoff M; Wagner H
    Verh Dtsch Ges Inn Med; 1974; 80():1584-6. PubMed ID: 4548989
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization of RFM mouse T lymphocyte anti-oncofetal antigen immunity in apparent tumor-free, long-term survivors of sublethal X-irradiation by limiting dilution T lymphocyte cloning.
    Rohrer JW; Culpepper C; Barsoum AL; Coggin JH
    J Immunol; 1995 Mar; 154(5):2266-80. PubMed ID: 7868899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
    Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
    Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A model for colon cancer immunology and immunotherapy: the PRO/REG cell variants].
    Martin F; Martin M
    Gastroenterol Clin Biol; 2000 Oct; 24(10):923-8. PubMed ID: 11084430
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.